Announcement • Jun 30
Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2026 Results on Aug 24, 2026 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report first half, 2026 results on Aug 24, 2026 New Risk • Jun 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (8.4% average weekly change). Declared Dividend • Jun 01
Dividend reduced to CN¥0.22 Dividend of CN¥0.22 is 45% lower than last year. Ex-date: 2nd June 2026 Payment date: 2nd June 2026 Dividend yield will be 1.2%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (18% cash payout ratio). The dividend has increased by an average of 5.5% per year over the past 10 years. However, payments have been volatile during that time. Announcement • May 29
Guangzhou Wondfo Biotech Co.,Ltd Announces Cash Dividend Implementation of Final Profit Distribution Plan (A Shares) for 2025 , Payable on 02 June 2026 Guangzhou Wondfo Biotech Co.,Ltd announced Dividend Implementation (Cash Only) of 2025 final profit distribution plan (A shares) as Cash dividend of CNY 2.20000000 per 10 shares (tax included). Record date: 01 June 2026. Ex-date: 02 June 2026. Payment date: 02 June 2026. Net cash dividend per 10 shares after tax: CNY 1.98000000(CNY 2.20000000- CNY 0.22000000). Reported Earnings • Apr 23
First quarter 2026 earnings released: EPS: CN¥0.18 (vs CN¥0.39 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.18 (down from CN¥0.39 in 1Q 2025). Revenue: CN¥581.7m (down 27% from 1Q 2025). Net income: CN¥84.4m (down 55% from 1Q 2025). Profit margin: 14% (down from 24% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Announcement • Apr 23
Guangzhou Wondfo Biotech Co.,Ltd, Annual General Meeting, May 15, 2026 Guangzhou Wondfo Biotech Co.,Ltd, Annual General Meeting, May 15, 2026, at 14:00 China Standard Time. Location: No. 8, Lizhishan Road, Science City, Huangpu District, Guangzhou, Guangdong China Announcement • Mar 31
Guangzhou Wondfo Biotech Co.,Ltd to Report Q1, 2026 Results on Apr 23, 2026 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report Q1, 2026 results on Apr 23, 2026 Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥25.56, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 27x in the Medical Equipment industry in China. Total loss to shareholders of 16% over the past three years. Price Target Changed • Jan 07
Price target increased by 7.8% to CN¥27.05 Up from CN¥25.08, the current price target is an average from 2 analysts. New target price is 35% above last closing price of CN¥20.00. Stock is down 8.6% over the past year. The company is forecast to post earnings per share of CN¥0.81 for next year compared to CN¥1.21 last year. Announcement • Dec 31
Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2025 Results on Apr 23, 2026 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report fiscal year 2025 results on Apr 23, 2026 New Risk • Oct 28
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (dividend per share is over 19x cash flows per share). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (10% net profit margin). Reported Earnings • Oct 26
Third quarter 2025 earnings released: CN¥0.12 loss per share (vs CN¥0.17 profit in 3Q 2024) Third quarter 2025 results: CN¥0.12 loss per share (down from CN¥0.17 profit in 3Q 2024). Revenue: CN¥444.5m (down 27% from 3Q 2024). Net loss: CN¥55.5m (down 169% from profit in 3Q 2024). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2025 Results on Oct 27, 2025 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report Q3, 2025 results on Oct 27, 2025 Announcement • Sep 23
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 60 million worth of its shares. Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces a share repurchase program. Under the program, the company will repurchase up to CNY 60 million worth of its shares. The shares will be repurchased at a price not more than CNY 34.66 per share. The company will use its own funds to repurchase company shares and use them all for employee stock ownership plans or equity incentives. The program will be valid for 6 months. Reported Earnings • Aug 20
Second quarter 2025 earnings released: EPS: CN¥0 (vs CN¥0.29 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0 (down from CN¥0.29 in 2Q 2024). Revenue: CN¥445.4m (down 38% from 2Q 2024). Net income: CN¥63.5k (down 100% from 2Q 2024). Profit margin: 0% (down from 19% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Announcement • Jul 02
Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2025 Results on Aug 26, 2025 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report first half, 2025 results on Aug 26, 2025 Announcement • May 13
Guangzhou Wondfo Biotech Co.,Ltd Approves Cash Dividend for the Year 2024 Guangzhou Wondfo Biotech Co.,Ltd announced at the AGM held on May 9, 2025, approved Cash dividend/10 shares (tax included) of CNY4.00000000 for the year 2024. Announcement • Apr 11
Guangzhou Wondfo Biotech Co.,Ltd Proposes Final Cash Dividend for the Year 2024 Guangzhou Wondfo Biotech Co.,Ltd proposed final cash dividend/10 shares (tax included) of CNY 4.00000000 for the year 2024. Reported Earnings • Apr 10
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥1.21 (up from CN¥1.10 in FY 2023). Revenue: CN¥3.06b (up 11% from FY 2023). Net income: CN¥561.6m (up 15% from FY 2023). Profit margin: 18% (in line with FY 2023). Revenue missed analyst estimates by 6.1%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Announcement • Apr 10
Guangzhou Wondfo Biotech Co.,Ltd, Annual General Meeting, May 09, 2025 Guangzhou Wondfo Biotech Co.,Ltd, Annual General Meeting, May 09, 2025, at 14:00 China Standard Time. Location: 3F, Tower D, No. 8, Lizhishan Road, Science City, Huangpu District, Guangzhou, Guangdong China Announcement • Mar 31
Guangzhou Wondfo Biotech Co.,Ltd to Report Q1, 2025 Results on Apr 25, 2025 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report Q1, 2025 results on Apr 25, 2025 Announcement • Dec 31
Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2024 Results on Mar 28, 2025 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report fiscal year 2024 results on Mar 28, 2025 Board Change • Nov 05
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Employee Supervisor Xiao Wei He was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.15 in 3Q 2023). Revenue: CN¥606.1m (up 18% from 3Q 2023). Net income: CN¥80.1m (up 23% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (8.2% increase in shares outstanding). Announcement • Sep 30
Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report Q3, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥22.96, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 18x in the Medical Equipment industry in China. Total loss to shareholders of 45% over the past three years. Reported Earnings • Aug 14
Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.30 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.29. Revenue: CN¥714.2m (up 8.7% from 2Q 2023). Net income: CN¥137.5m (up 5.1% from 2Q 2023). Profit margin: 19% (in line with 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Price Target Changed • Jul 09
Price target decreased by 7.6% to CN¥33.55 Down from CN¥36.30, the current price target is an average from 2 analysts. New target price is 36% above last closing price of CN¥24.61. Stock is down 9.1% over the past year. The company is forecast to post earnings per share of CN¥1.38 for next year compared to CN¥1.10 last year. Announcement • Jun 29
Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2024 Results on Aug 14, 2024 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report first half, 2024 results on Aug 14, 2024 Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥26.90, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Medical Equipment industry in China. Total loss to shareholders of 64% over the past three years. Reported Earnings • Apr 22
First quarter 2024 earnings released: EPS: CN¥0.49 (vs CN¥0.46 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.49 (up from CN¥0.46 in 1Q 2023). Revenue: CN¥861.1m (up 3.5% from 1Q 2023). Net income: CN¥218.3m (up 7.2% from 1Q 2023). Profit margin: 25% (in line with 1Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings. New Risk • Apr 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (203% cash payout ratio). Profit margins are more than 30% lower than last year (12% net profit margin). Shareholders have been diluted in the past year (6.4% increase in shares outstanding). Announcement • Mar 30
Guangzhou Wondfo Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 22, 2024 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report Q1, 2024 results on Apr 22, 2024 Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥23.04, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 65% over the past three years. Announcement • Dec 29
Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2023 Results on Apr 22, 2024 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report fiscal year 2023 results on Apr 22, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: EPS: CN¥0.15 (up from CN¥0.14 in 3Q 2022). Revenue: CN¥515.8m (down 22% from 3Q 2022). Net income: CN¥65.3m (up 5.4% from 3Q 2022). Profit margin: 13% (up from 9.4% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 6.4%. Earnings per share (EPS) also missed analyst estimates by 29%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Announcement • Sep 30
Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2023 Results on Oct 26, 2023 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report Q3, 2023 results on Oct 26, 2023 Reported Earnings • Aug 16
Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.62 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.30 (down from CN¥0.62 in 2Q 2022). Revenue: CN¥657.0m (down 53% from 2Q 2022). Net income: CN¥130.8m (down 52% from 2Q 2022). Profit margin: 20% (in line with 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Announcement • Jul 07
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares. Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces a share repurchase program. Under the program, the company will repurchase up to CNY 50 million worth of its shares. The shares will be repurchased at a price not more than CNY 43.06 per share. The company will use its own funds to repurchase company shares and use them all for employee stock ownership plans or equity incentives. The program will be valid for 6 months. Reported Earnings • Apr 01
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: EPS: CN¥2.71 (up from CN¥1.43 in FY 2021). Revenue: CN¥5.68b (up 69% from FY 2021). Net income: CN¥1.20b (up 89% from FY 2021). Profit margin: 21% (up from 19% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 14%. Revenue is expected to decline by 10% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in China are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Buying Opportunity • Feb 13
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be CN¥43.18, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 36% over the last 3 years. Earnings per share has grown by 40%. Revenue is forecast to decline by 18% in 2 years. Earnings is forecast to decline by 12% in the next 2 years. Buying Opportunity • Dec 20
Now 20% undervalued Over the last 90 days, the stock is up 25%. The fair value is estimated to be CN¥46.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 36% over the last 3 years. Earnings per share has grown by 40%. Revenue is forecast to decline by 17% in 2 years. Earnings is forecast to decline by 11% in the next 2 years. Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥39.21, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 23x in the Medical Equipment industry in China. Total returns to shareholders of 4.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥46.74 per share. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥48.00, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 25x in the Medical Equipment industry in China. Total returns to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥51.12 per share. Buying Opportunity • Nov 23
Now 23% undervalued Over the last 90 days, the stock is up 10%. The fair value is estimated to be CN¥51.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 36% over the last 3 years. Earnings per share has grown by 40%. Revenue is forecast to decline by 6.2% in 2 years. Earnings is forecast to grow by 3.4% in the next 2 years. Price Target Changed • Nov 22
Price target decreased to CN¥60.42 Down from CN¥68.73, the current price target is an average from 3 analysts. New target price is 48% above last closing price of CN¥40.90. Stock is up 10% over the past year. The company is forecast to post earnings per share of CN¥2.91 for next year compared to CN¥1.43 last year. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥34.18, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 25x in the Medical Equipment industry in China. Total loss to shareholders of 9.1% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥51.23 per share. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.16 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.14 (down from CN¥0.16 in 3Q 2021). Revenue: CN¥662.8m (up 1.8% from 3Q 2021). Net income: CN¥62.0m (down 13% from 3Q 2021). Profit margin: 9.4% (down from 11% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is expected to decline by 1.3% p.a. on average during the next 3 years, while revenues in the Medical Equipment industry in China are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥32.98, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 26x in the Medical Equipment industry in China. Total loss to shareholders of 17% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥42.15 per share. Announcement • Sep 27
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares. Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces a share repurchase program. Under the program, the company will repurchase up to CNY 50 million worth of its shares. The shares will be repurchased at a price not more than CNY 49.72 per share. The purpose of the program is to implement ESOP or equity incentive plans. The program will be valid for 6 months. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.90 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.62 (down from CN¥0.90 in 2Q 2021). Revenue: CN¥1.41b (up 21% from 2Q 2021). Net income: CN¥274.4m (down 31% from 2Q 2021). Profit margin: 20% (down from 35% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to stay flat compared to a 26% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Aug 20
Guangzhou Wondfo Biotech Co.,Ltd announced that it expects to receive CNY 1 billion in funding Guangzhou Wondfo Biotech Co.,Ltd announced that it will issue common shares to raise up to CNY 1,000,000,000 on August 19, 2022. Announcement • Jun 09
Guangzhou Wondfo Biotech Co.,Ltd Announces Cash Dividend, Payable on 14 June 2022 Guangzhou Wondfo Biotech Co.,Ltd announced 2021 final profit distribution plan to be implemented (A shares) as Cash dividend/10 shares (tax included): CNY 3.00000000. Record date as 13 June 2022, ex-date as 14 June 2022 and payment date as 14 June 2022. Announcement • May 24
Guangzhou Wondfo Biotech Co.,Ltd Approves Cash Dividend for the Year 2021 Guangzhou Wondfo Biotech Co.,Ltd approved Cash dividend/10 shares (tax included) of CNY 3.00000000 for the year 2021, at its Annual General Meeting of 2021 held on 20 May 2022. Major Estimate Revision • May 01
Consensus revenue estimates increase by 34% The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from CN¥4.20b to CN¥5.61b. EPS estimate increased from CN¥2.35 to CN¥2.98 per share. Net income forecast to shrink 5.8% next year vs 35% growth forecast for Medical Equipment industry in China . Consensus price target down from CN¥68.73 to CN¥63.73. Share price fell 6.3% to CN¥43.63 over the past week. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Apr 26
Guangzhou Wondfo Biotech Co.,Ltd. Announces Profit Distribution Proposal for 2021 Guangzhou Wondfo Biotech Co.,Ltd announced the profit distribution proposal for 2021. The company announced Cash dividend/10 shares (tax included) of CNY 3.00000000. Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥52.33, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 21x in the Medical Equipment industry in China. Total returns to shareholders of 104% over the past three years. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improved over the past week After last week's 39% share price gain to CN¥61.98, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 25x in the Medical Equipment industry in China. Total returns to shareholders of 127% over the past three years. Valuation Update With 7 Day Price Move • Feb 28
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥46.26, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 25x in the Medical Equipment industry in China. Total returns to shareholders of 87% over the past three years. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.27 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥650.9m (up 15% from 3Q 2020). Net income: CN¥71.6m (down 39% from 3Q 2020). Profit margin: 11% (down from 21% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Price Target Changed • Sep 14
Price target decreased to CN¥68.96 Down from CN¥78.06, the current price target is an average from 5 analysts. New target price is 72% above last closing price of CN¥39.98. Stock is down 40% over the past year. Announcement • Sep 08
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 80 million worth of its shares. Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces a share repurchase program. Under the program, the company will repurchase up to CNY 80 million worth of its shares. The shares will be repurchased at a price not more than CNY 77.92 per share. The purpose of the program is to implement equity incentive plans. The program will be funded from company's own funds. The program will be valid for 6 months. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.79 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥1.16b (up 9.9% from 2Q 2020). Net income: CN¥400.2m (up 14% from 2Q 2020). Profit margin: 35% (up from 33% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥43.56, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 36x in the Medical Equipment industry in China. Total returns to shareholders of 70% over the past three years. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥63.22, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 39x in the Medical Equipment industry in China. Total returns to shareholders of 125% over the past three years. Announcement • May 21
Guangzhou Wondfo Biotech Co.,Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 26 May 2021 Guangzhou Wondfo Biotech Co.,Ltd announced 2020 final profit distribution plan to be implemented (A shares) of CNY 5.00000000 per 10 shares (tax included), with Record date: 25 May 2021; Ex-date: 26 May 2021; and Payment date: 26 May 2021. Reported Earnings • Apr 30
First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.29 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥696.6m (up 26% from 1Q 2020). Net income: CN¥155.4m (up 59% from 1Q 2020). Profit margin: 22% (up from 18% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year whereas the company’s share price has increased by 35% per year. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥101, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 37x in the Medical Equipment industry in China. Total returns to shareholders of 144% over the past three years. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥1.87 (vs CN¥1.14 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.81b (up 36% from FY 2019). Net income: CN¥634.2m (up 64% from FY 2019). Profit margin: 23% (up from 19% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth. Announcement • Feb 24
Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2020 Results on Mar 31, 2021 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report fiscal year 2020 results on Mar 31, 2021 Announcement • Feb 02
Wondfo Rams Up Neutralizing Antibody, Antigen and PCR Tests to Address the Evolving Demands for COVID-19 Testing Globally Wondfo is ramping up neutralizing antibody, antigen and PCR tests to address the evolving demands for COVID-19 testing globally. As countries draw up plans to deal with the new wave of infections amidst the pandemic while vaccination programmes are rolled out, Wondfo remains resolute and agile to provide healthcare authorities with the specific tests they need to apply appropriate testing strategies that can help bring the pandemic under control. Testing is crucial as it informs effective mass intervention programmes that can also minimise disruption to economic activities. However, during a pandemic of such size and scale, it is difficult for countries to determine a perfect testing strategy, as there is no one-size-fits-all approach. It is not only impossible for countries to rely on one 'gold standard' test, they cannot adopt the exact same strategies due to varying demographics, infrastructure, cultural attitudes, and economic capacity. Testing is a nuanced process. When determining which type of test to use, key aspects such as changes in the course of the disease and the nature of the tests available need to be incorporated. Depending on the time of the appearance of coronavirus and the presence of the two types of antibodies in the human body (IgG or IgM) designed to fight it, PCR and antigen tests are suitable tests in the early onset period (WHO guidelines recommend the use of PCR and antigen tests for triage), while antibody tests are suitable later on when antibodies are produced over days to weeks after infection with the virus and in even larger numbers with a second infection. In addition, the studies of neutralizing antibodies, those that prevent or treat disease, can aid in the development and evaluation of vaccines. PCR tests are considered the 'gold standard' for COVID-19 testing. The WHO has advised PCR tests should be the recommended method for the identification and laboratory confirmation of COVID-19 cases. However, PCR requires laboratory processing techniques and can take up to 48 hours. In comparison, antigen and antibody tests, also known as rapid tests, can return a result in 15-30 minutes and play a valuable role in screening, disease surveillance and epidemiologic research. Is New 90 Day High Low • Jan 22
New 90-day high: CN¥95.02 The company is up 19% from its price of CN¥80.03 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥46.98 per share. Is New 90 Day High Low • Dec 25
New 90-day high: CN¥90.79 The company is up 7.0% from its price of CN¥84.76 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥40.76 per share. Valuation Update With 7 Day Price Move • Dec 25
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥90.79, the stock is trading at a trailing P/E ratio of 46.6x, up from the previous P/E ratio of 40x. This compares to an average P/E of 43x in the Medical Equipment industry in China. Total returns to shareholders over the past three years are 126%. Is New 90 Day High Low • Nov 06
New 90-day low: CN¥74.05 The company is down 20% from its price of CN¥92.86 on 07 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥33.62 per share. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥663.2m, up 77% from the prior year. Total revenue was CN¥2.82b over the last 12 months, up 47% from the prior year. Is New 90 Day High Low • Oct 22
New 90-day low: CN¥81.99 The company is down 12% from its price of CN¥93.50 on 24 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥34.28 per share. Is New 90 Day High Low • Sep 30
New 90-day low: CN¥83.05 The company is down 15% from its price of CN¥98.04 on 02 July 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥33.64 per share. Announcement • Aug 13
Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2020 Results on Aug 28, 2020 Guangzhou Wondfo Biotech Co.,Ltd announced that they will report first half, 2020 results on Aug 28, 2020 
